转自：新华财经 在此之前，片仔癀药业还参与了第四届中非经贸博览会，面向非洲及全球客商展现中医药文化的深厚底 蕴与创新活力，为片仔癀药业"出海"积极寻求更多全球合作新机。 值得注意的是，片仔癀药业此次亮相也是加快转型融合的一道缩影，旨在加速触达Z世代消费群体，推 动传统中医药与现代健康理念相融合。 这与片仔癀药业近年来深耕核心产品线，同时发力打造大健康版图不谋而合，在化妆品、日化、保健食 品等领域持续开展探索，将传统中医药文化与现代养生文化、美容时尚文化有机结合。 与此同时，片仔癀药业持续强化研发布局，进一步完善研发管线。上半年积极推进2个新药立项，推动 18个在研新药及经典名方的研发项目。 据悉，未来，片仔癀药业将继续深耕中医药领域，积极推动产业现代化与国际化进程，以创新发展理念 实现中医药企业转型升级，重构国货医药品牌价值。 9月3日，漳州片仔癀药业股份有限公司携手京东健康"国药盛典"登陆纽约时报广场，此次跨界合作标志 着片仔癀药业"出海"提速，中医药国际化传播迈出坚实一步。随着海上丝绸之路的开拓，片仔癀连续多 年位居中国中成药外贸单项品种出口前列，在海外华人圈有着很高的知名度和美誉度，是海上丝绸之路 上一 ...

Core Points - The China Listed Companies Association has officially released the 2025 cash dividend ranking, with Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. making the list due to its long-standing commitment to sharing development results with investors [1][4] - Pien Tze Huang has maintained a consistent cash dividend policy since its A-share market debut in 2003, with a total dividend payout exceeding 7.7 billion yuan over 22 years [4] - For 2024, the company plans to distribute a total cash dividend of 1.792 billion yuan, representing 60.19% of the annual net profit attributable to shareholders, reflecting a strong financial foundation and operational stability [4] Company Performance - In 2024, despite a complex market environment, Pien Tze Huang achieved steady growth, with increasing revenue and an expanded market share for its core Pien Tze Huang product series [4] - The company has been optimizing its industrial layout by increasing investments in traditional Chinese medicine research and smart manufacturing, significantly enhancing its overall competitiveness [4] Future Outlook - Pien Tze Huang aims to continue its long-term win-win philosophy with investors, adhering to regulatory requirements for cash dividends and enhancing the stability, sustainability, and predictability of its dividend planning [4]